Companies › BrightGene Bio-Medical Technology
2 active drug programs in 13 registered trials: 7 Phase 1, 4 Phase 3, 2 Phase 2; Metabolic and endocrine, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BGM0504 Injection multi-dose pen GLP-1 receptor agonist | – | Phase 3 | Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes (T2DM); Obesity; Overweight or Obese Participants Without Diabetes … | Nov 2026 |
| BGM1812 | – | Phase 1 | Overweight or Obesity; Healhty | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06911203 | BGM0504 Injection multi-dose pen | Phase 2 | Obesity | Metabolic and endocrine | Jan 2026 |
| NCT07239973 | BGM0504 Injection multi-dose pen | Phase 1 | Healthy | Metabolic and endocrine | Mar 2026 |
| NCT07166081 | BGM0504 Injection multi-dose pen | Phase 1 | Non-diabetic Overweight or Obese | Metabolic and endocrine | Mar 2026 |
| NCT07382908 | BGM0504 Injection multi-dose pen | Phase 1 | Overweight/Obesity | Metabolic and endocrine | Apr 2026 |
| NCT07382908 | BGM0504 Injection multi-dose pen | Phase 1 | Overweight/Obesity | Metabolic and endocrine | Apr 2026 |
| NCT07294235 | BGM1812 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Jun 2026 |
| NCT07224399 | BGM1812 | Phase 1 | Healhty | Metabolic and endocrine | Jul 2026 |
| NCT07566572 | BGM0504 Injection multi-dose pen | Phase 1 | Chinese Healthy Volunteers | Other | Aug 2026 |
| NCT06716216 | BGM0504 Injection multi-dose pen | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Nov 2026 |
| NCT06716203 | BGM0504 Injection multi-dose pen | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Nov 2026 |
| NCT07658560 | BGM0504 Injection multi-dose pen | Phase 2 | Overweight or Obese Participants Without Diabetes | Metabolic and endocrine | Feb 2027 |
| NCT07064486 | BGM0504 Injection multi-dose pen | Phase 3 | Type 2 Diabetes (T2DM) | Metabolic and endocrine | Apr 2027 |
| NCT07743983 | BGM0504 Injection multi-dose pen | Phase 3 | Type 2 Diabetes (T2DM) | Metabolic and endocrine | Sep 2028 |
No annotated target.
–
Beijing QL Biopharmaceutical Energenesis Biomedical JCR Pharmaceuticals Viking Therapeutics OPKO Health
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.